Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$110.03 USD
-3.15 (-2.78%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $110.02 -0.01 (-0.01%) 7:04 PM ET
3-Hold of 5 3
A Value C Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$110.03 USD
-3.15 (-2.78%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $110.02 -0.01 (-0.01%) 7:04 PM ET
3-Hold of 5 3
A Value C Growth F Momentum B VGM
Zacks News
Why Is Jazz (JAZZ) Up 4.8% Since Last Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jazz Pharma (JAZZ) Misses on Q1 Earnings & Sales, Cuts View
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports lower-than-expected first-quarter 2020 earnings and revenues. It lowers its guidance for 2020. Shares drop.
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of -31.82% and -0.68%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Jazz Pharmaceuticals (JAZZ) Ahead of Earnings?
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Jazz Pharmaceuticals (JAZZ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Jazz (JAZZ) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Is Jazz (JAZZ) Down 18% Since Last Earnings Report?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jazz's (JAZZ) Xyrem Follow-On Candidate NDA Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts Jazz's (JAZZ) regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem in the United States.
Jazz Pharma (JAZZ) Surpasses Q4 Earnings & Sales Estimates
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) beats fourth-quarter 2019 earnings and revenue estimates. It issues guidance for 2020.
Jazz Pharmaceuticals (JAZZ) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of 6.25% and 3.23%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
What Awaits Jazz Pharmaceuticals (JAZZ) in Q4 Earnings?
by Zacks Equity Research
Progress of its pipeline candidates and launch of Sunosi is likely to have increased Jazz Pharmaceuticals (JAZZ) operating expenses in the fourth quarter. Xyrem likely to have continued strong demand trend.
ImmunoGen (IMGN) Q4 Earnings & Sales Beat, Shares Rally
by Zacks Equity Research
ImmunoGen (IMGN) reports fourth-quarter results with earnings and revenues beating estimates.
Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258 (Revised)
by Zacks Equity Research
Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.
Why Jazz (JAZZ) Could Beat Earnings Estimates Again
by Zacks Equity Research
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258
by Zacks Equity Research
Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.
Jazz's (JAZZ) New Sleep Drug Sunosi Gets Approval in Europe
by Zacks Equity Research
Jazz (JAZZ) receives approval for Sunosi as a treatment for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea patients in Europe.
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Jazz Enrolls First Patient in Phase II/III Leukemia Study
by Zacks Equity Research
Jazz (JAZZ) begins enrollment in the phase II/III study evaluating JZP-458 for treating pediatric and adult patients with acute lymphoblastic leukemia, hypersensitive to E. coli-derived asparaginases
Zacks.com featured highlights include: Lithia Motors, Marathon Petroleum, Meritage Homes, Jazz Pharmaceuticals and Barclays PLC
by Zacks Equity Research
Zacks.com featured highlights include: Lithia Motors, Marathon Petroleum, Meritage Homes, Jazz Pharmaceuticals and Barclays PLC
7 Impressive Growth Stocks to Buy for 2020
by Debanjana Dey
The prospects of growth stocks appear bright for 2020, making the following companies attractive bets.
Are Investors Undervaluing Jazz Pharmaceuticals (JAZZ) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
5 High Earnings Yield Stocks for a Standout Portfolio
by Zacks Equity Research
If you are not sure whether to invest your money in bonds or stocks, a key parameter that can show you the right direction is earnings yield.
Create a Value-Based Portfolio With These 4 Low P/CF Stocks
by Sumit Singh
Investing in stocks based on value analysis is generally considered one of the best practices. In value investing, investors pick stocks that are usually cheap but fundamentally sound.
Is Jazz Pharmaceuticals (JAZZ) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (JAZZ) Outperforming Other Medical Stocks This Year?
Jazz (JAZZ) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Jazz (JAZZ) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.